Promius reports Phase II data for DFN-02 in migraine

In September, the Promius Pharma LLC subsidiary of Dr. Reddy's Laboratories Ltd. (NYSE:RDY) reported data from a Phase II trial in 107 patients with episodic migraine showing that intranasal DFN-02 significantly increased the proportion of patients with migraine

Read the full 380 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE